Justia Class Action Opinion Summaries

In 2015, product liability cases involving the blood-pressure medication Olmesartan were consolidated into a multidistrict litigation (MDL) in the United States District Court for the District of New Jersey. Adam Slater and his law firm, Mazie Slater Katz & Freeman, LLC, represented over 200 plaintiffs, and the case settled for over $300 million. Subsequently, Anthony Martino, a plaintiff in the MDL, filed a class action in New Jersey state court against his former lawyers, alleging they received contingent fees in violation of New Jersey court rules. The case was removed to federal court and dismissed, with the dismissal affirmed on appeal.Following this, twenty-one individuals represented by the same defendants in the MDL filed a similar action in New Jersey state court, alleging breach of contract, legal malpractice, conversion, and unjust enrichment. Defendants removed the case to the District Court, citing diversity and federal-question jurisdiction. The District Court denied the plaintiffs' motion to remand, asserting ancillary enforcement jurisdiction, and granted defendants' motion for judgment on the pleadings, applying issue preclusion. The court also dismissed the parties' motions for sanctions as moot.The United States Court of Appeals for the Third Circuit reviewed the case. The court held that ancillary enforcement jurisdiction does not confer original jurisdiction sufficient for removal under 28 U.S.C. § 1441(a). The court also found that the plaintiffs' state-law claims did not necessarily raise a federal issue to establish federal-question jurisdiction. The court vacated the District Court's judgment and remanded the case to determine if the amount in controversy exceeded $75,000 for diversity jurisdiction. Additionally, the court vacated the order dismissing the motions for sanctions as moot, instructing the District Court to consider the merits of each motion. View "Johnson v. Mazie" on Justia Law

Plaintiffs in this multi-district products liability suit allege that they purchased defective Chrysler Pacifica minivans from FCA, which were recalled due to a risk of battery explosions. After the recall, plaintiffs filed seven putative class action suits, which were consolidated in the Eastern District of Michigan. During discovery, FCA discovered that some plaintiffs had agreed to arbitration clauses when purchasing their minivans and moved to compel arbitration for those plaintiffs. The district court denied FCA’s motion, finding that FCA had waived its right to arbitrate by moving to dismiss the entire complaint.The United States District Court for the Eastern District of Michigan denied FCA’s motion to compel arbitration, concluding that FCA had waived its right to arbitrate by engaging in litigation conduct inconsistent with that right, specifically by moving to dismiss the plaintiffs’ claims. The district court made this finding sua sponte, without the plaintiffs raising the issue of waiver.The United States Court of Appeals for the Sixth Circuit reviewed the case and reversed the district court’s decision. The appellate court held that a party cannot waive its right to arbitration without knowledge of that right. The court found that FCA did not know about the arbitration clauses until it obtained the relevant purchase agreements through discovery. Additionally, the appellate court determined that the district court erred by raising the issue of waiver on its own, violating the principle of party presentation. The Sixth Circuit concluded that the district court’s decision was clearly erroneous and remanded the case for further proceedings consistent with its opinion. View "Berzanskis v. FCA US, LLC" on Justia Law

Plaintiffs MSP Recovery Claims, Series LLC; MSPA Claims 1, LLC; and Series PMPI filed a lawsuit in September 2018 against Fresenius Medical Care Holdings and related entities, alleging negligence, product liability, and design defect claims related to the GranuFlo product used in hemodialysis treatments. The claims arose from a 2012 public memorandum by Fresenius that GranuFlo could lead to cardiopulmonary arrest. The plaintiffs argued that the statute of limitations was tolled by a putative class action filed in 2013 (the Berzas action) in the Eastern District of Louisiana, which was later transferred to the District of Massachusetts as part of multidistrict litigation (MDL).The District Court for the District of Massachusetts dismissed the plaintiffs' claims as time-barred, concluding that the Berzas action ceased to be a class action by June 2014 when the named plaintiffs filed Short Form Complaints or stipulations of dismissal, which did not include class allegations. The court also noted that the Berzas plaintiffs did not pursue class certification actively, and the case was administratively closed in April 2019.The United States Court of Appeals for the First Circuit affirmed the district court's decision. The First Circuit held that the Berzas action lost its class action status by June 2014, and any tolling under American Pipe & Construction Co. v. Utah ended at that time. The court reasoned that allowing indefinite tolling based on an inactive class certification request would contravene the principles of efficiency and economy in litigation. Therefore, the plaintiffs' 2018 complaint was untimely, and the district court's dismissal was upheld. View "MSP Recovery Claims, Series LLC v. Fresenius Medical Care Holdings, Inc." on Justia Law

In late 2019, a hospital sent letters to over a thousand patients, including Linda Gierek, informing them of potential exposure to infectious diseases due to a technician's failure to fully sterilize surgical instruments. Gierek filed a class-action complaint against the hospital, asserting claims of negligent infliction of emotional distress, negligence, and medical malpractice. She sought class certification for similarly situated patients and their spouses. The trial court consolidated Gierek’s action with a similar class-action claim filed by Cheyanne Bennett.The Indiana Patient’s Compensation Fund intervened, arguing that the claims sounded in ordinary negligence and thus the Medical Malpractice Act (MMA) did not apply. The hospital argued the opposite. The trial court ruled in favor of the hospital, stating the MMA applied, and denied the motion for class certification, citing lack of subject-matter jurisdiction while a proposed complaint was pending before a medical-review panel. On appeal, the Court of Appeals affirmed the MMA’s applicability but reversed the trial court’s decision on class certification jurisdiction.The Indiana Supreme Court reviewed the case and held that the MMA covers all claims for medical malpractice, not limited to bodily injury or death. The court also held that class certification is a proper preliminary determination under the MMA. The court affirmed in part, reversed in part, and remanded the case for the trial court to consider the plaintiffs’ motion for class certification. View "Gierek v. Anonymous 1" on Justia Law

The case involves the plaintiffs, including the estate of Carson Bride and three minors, who suffered severe harassment and bullying through the YOLO app, leading to emotional distress and, in Carson Bride's case, suicide. YOLO Technologies developed an anonymous messaging app that promised to unmask and ban users who engaged in bullying or harassment but allegedly failed to do so. The plaintiffs filed a class action lawsuit against YOLO, claiming violations of state tort and product liability laws.The United States District Court for the Central District of California dismissed the plaintiffs' complaint, holding that Section 230 of the Communications Decency Act (CDA) immunized YOLO from liability. The court found that the claims sought to hold YOLO responsible for third-party content posted on its app, which is protected under the CDA.The United States Court of Appeals for the Ninth Circuit reviewed the case. The court reversed the district court's dismissal of the plaintiffs' misrepresentation claims, holding that these claims were based on YOLO's promise to unmask and ban abusive users, not on a failure to moderate content. The court found that the misrepresentation claims were analogous to a breach of promise, which is not protected by Section 230. However, the court affirmed the dismissal of the plaintiffs' product liability claims, holding that Section 230 precludes liability because these claims attempted to hold YOLO responsible as a publisher of third-party content. The court concluded that the product liability claims were essentially about the failure to moderate content, which is protected under the CDA. View "Estate of Bride v. Yolo Technologies, Inc." on Justia Law

The case involves nine lawsuits filed in Connecticut state court, each asserting state-law personal injury claims related to the use of Zantac. The plaintiffs, represented by the same firm, structured their complaints to avoid federal jurisdiction by including fewer than 100 plaintiffs per suit and ensuring that each suit included a Connecticut plaintiff. The plaintiffs filed a motion to consolidate these actions, citing Connecticut Practice Book § 9-5, which the defendants argued proposed a joint trial, thus triggering federal jurisdiction under the Class Action Fairness Act (CAFA).The United States District Court for the District of Connecticut remanded the cases to state court, finding that the plaintiffs' motion to consolidate was intended only for pretrial purposes, not for a joint trial. The district court noted that the plaintiffs' motion cited authority that could be used for either pretrial management or a joint trial but concluded that the context indicated a pretrial purpose, especially given the plaintiffs' efforts to avoid federal jurisdiction.The United States Court of Appeals for the Second Circuit reviewed the case and affirmed the district court's decision. The appellate court held that CAFA requires a determination of whether the plaintiffs intended to seek a joint trial. The court found that the plaintiffs' motion, when read in context, proposed only pretrial consolidation. The court emphasized that the plaintiffs' consistent efforts to avoid federal jurisdiction supported this interpretation. Thus, the appellate court concluded that the defendants did not meet their burden to demonstrate that federal jurisdiction existed under CAFA. View "Bacher v. Boehringer Ingelheim Pharmaceuticals, Inc." on Justia Law

In this toxic tort case, about 170 individuals allege that they were harmed by lead paint pigment. The plaintiffs, who were joined together in a single complaint, brought claims against several manufacturers of the pigment. After a series of trials, the district court granted summary judgment for the defendants on all claims. The court then extended these rulings to the remaining plaintiffs on law of the case and issue preclusion grounds. The United States Court of Appeals for the Seventh Circuit affirmed the district court's decision in large part but reversed in small part. The appellate court held that the law of the case doctrine properly applied to a group of plaintiffs who had opted to proceed under a single complaint and whose claims were sunk after summary judgment. However, the court reversed the district court's decision as to a small group of plaintiffs who filed their own cases, noting that due process protects their right to try their claims. The court also rejected the plaintiffs' request to revisit or certify certain questions addressed in a prior ruling, and affirmed that ruling based on the principle of stare decisis. View "Allen v. Armstrong Containers Inc." on Justia Law

In this case, the Supreme Court of the State of Washington was asked to consider a class action suit brought by patients against MultiCare Health System, Inc., a Washington corporation that operates Good Samaritan Hospital. The suit arose after a nurse employed by MultiCare, Cora Weberg, improperly diverted injectable narcotics for her own use and infected some emergency department patients with hepatitis C. The patients claimed that MultiCare failed to meet the accepted standard of care in supervising and hiring Nurse Weberg. The trial court divided the class into two groups: those who were assigned to Nurse Weberg and those who were not. It then dismissed the claims of the second group. The trial court ruled that legal causation was not satisfied because Nurse Weberg did not directly treat these patients. The Court of Appeals affirmed this decision.However, the Supreme Court of the State of Washington reversed both courts and held that legal causation is satisfied. The court held that both classes can proceed with their chapter 7.70 RCW claims, which govern civil actions for damages for injury occurring as a result of health care. The court reasoned that the General Treatment Class's injuries arose as a result of health care, allowing their claim under chapter 7.70 RCW to proceed. The court also found that legal causation is satisfied when a hospital’s negligent supervision and hiring potentially exposes patients to a bloodborne pathogen, inducing fear and requiring blood testing. Thus, the court concluded that the General Treatment Class's claims should not have been dismissed. View "M.N. v. MultiCare Health Sys., Inc." on Justia Law

In the case before the United States Court of Appeals for the Fourth Circuit, plaintiff Carla J. Kappel, acting on behalf of her deceased ex-husband's estate and as mother to their minor children, sued LL Flooring, Inc., alleging that the company's Chinese-manufactured laminate flooring caused her ex-husband's death due to exposure to formaldehyde.The district court dismissed Kappel's wrongful death lawsuit, arguing that her claim was barred by a settlement agreement that had been reached in connection with two multidistrict litigation (MDL) actions related to LL Flooring's products. The court maintained that the deceased, Mr. Tarabus, was a class member subject to that settlement agreement and thus his claims, including any claims involving bodily injuries or death caused by the subject flooring, had been settled.On appeal, Kappel argued that the district court lacked subject matter jurisdiction to make the dismissal order and that the MDL settlement agreement did not bar her wrongful death lawsuit on behalf of the children. The Court of Appeals agreed with Kappel's latter argument and held that the settlement agreement failed to resolve Kappel’s wrongful death lawsuit.The Court found that the claims in Kappel's lawsuit, which concerned the bodily injuries Mr. Tarabus experienced and the alleged causal connection between the laminate flooring and his cancer diagnosis, were materially distinct from the claims in the MDL proceedings. Notably, the settlement class representatives had twice made clear that they were not pursuing personal injury claims on a class-wide basis, and at no point did any class representative ever allege or pursue a wrongful death lawsuit.Therefore, the Court vacated the lower court's dismissal of Kappel's lawsuit and remanded the case for further proceedings. View "Kappel v. LL Flooring, Inc." on Justia Law

Hardwick alleged that his bloodstream contains trace quantities of five chemicals (PFAS)—which are part of a family of thousands of chemicals used in medical devices, automotive interiors, waterproof clothing, food packaging, firefighting foam, non-stick cookware, ski and car waxes, batteries, semiconductors, aviation and aerospace construction, paints and varnishes, and building materials. Hardwick, who was exposed to firefighting foam, does not know what companies manufactured the particular chemicals in his bloodstream; nor does he know whether those chemicals might someday make him sick. Of the thousands of companies that have manufactured PFAS since the 1950s, Hardwick sued 10 defendants and sought to represent a class comprising nearly every person “residing in the United States.” The district court certified a class comprising every person residing in Ohio with trace amounts of certain PFAS in their blood.The Sixth Circuit remanded with instructions to dismiss the case. Even at the pleadings stage, the factual allegations, taken as true, “must be enough to raise a right to relief above the speculative level.” The element of traceability requires a showing that the plaintiff’s “injury was likely caused by the defendant.” The district court treated the defendants as a collective, but “standing is not dispensed in gross.” Even if Hardwick met the actual-injury requirement he must tie his injury to each defendant.” Hardwick’s conclusory allegations do not support a plausible inference that any of the defendants bear responsibility for the PFAS in Hardwick’s blood. View "Hardwick v. 3M Co." on Justia Law